5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Phase A, individuals will receive diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Added individuals will probably be enrolled at the discovered monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will